IIM
VRTX icon

Ivory Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Ivory Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-66,463
Closed -$5.8M – 89
2016
Q3 		$5.8M Buy
+66,463
New +$6.28M 0.17% 74

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Ivory Investment Management's VRTX Position: Q4 2016 in Review

Ivory Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2016, closing a stake of 66,463 shares — an estimated $5.8M sold.

Ivory Investment Management first reported a position in VRTX in Q3 2016 and held it in 1 quarter. The position peaked at $5.8M in Q3 2016. 483 funds tracked by Wall St. Rank hold VRTX as of Q4 2016.

  • Ivory Investment Management reported no remaining Vertex Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Ivory Investment Management sold 66,463 Vertex Pharmaceuticals shares in Q4 2016, an estimated $5.8M.
  • Ivory Investment Management first reported a position in Vertex Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Ivory Investment Management's Vertex Pharmaceuticals position peaked at $5.8M in Q3 2016.
  • 483 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2016.

Based on Ivory Investment Management's 13F filing for Q4 2016, filed 14 Feb 2017.